Sino Biopharmaceutical Limited

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:09 2025-06-13 am EDT			5-day change	1st Jan Change
5.530 ^HKD	-2.81%		+21.54%	+72.81%

Jun. 10	Sino Biopharmaceutical Updates On Phase III Registrational Clinical Study Of TQB2868 Injection	RE
Jun. 10	Sino Biopharmaceutical Limited Announces Approval Obtained from CDE to Initiate Phase III Registrational Clinical Study of TQB2868 Injection "PD-1/TGF Bi-Functional Fusion Protein"	CI

Sino Biopharmaceutical Updates On Phase III Registrational Clinical Study Of TQB2868 Injection

Published on 06/10/2025 at 06:29

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Sino Biopharmaceutical Limited

Sino Biopharmaceutical Updates On Phase III Registrational Clinical Study Of TQB2868 Injection	Jun. 10	RE
Sino Biopharmaceutical Limited Announces Approval Obtained from CDE to Initiate Phase III Registrational Clinical Study of TQB2868 Injection "PD-1/TGF Bi-Functional Fusion Protein"	Jun. 10	CI
Sino Biopharmaceutical Says Tqc3721 Inhalation Suspension Approved By Center For Drug Evaluation	Jun. 09	RE
Sino Biopharmaceutical Limited Presents Latest Results of the Phase III Clinical Study for Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Maintenance Treatment for Non-Small Cell Lung Cancer	Jun. 05	CI
Sino Biopharm Presents Lung Cancer Drug Trial Data at US Oncology Conference	Jun. 05	MT
Sino Biopharmaceutical Limited Presents Latest Results of the Phase III Clinical Study for Benmelstobart in Combination with Anlotinib Hydrochloride Capsules	Jun. 03	CI
Sino Biopharm Presents Lung Cancer Study Data at American Oncology Conference	Jun. 03	MT
Sino Biopharm Presents Cancer Drug Data at Oncology Conference	May. 28	MT
Sino Biopharmaceutical Limited Presents the Preliminary Data from the First-In-Human Phase I Clinical Study for TQB2102	May. 27	CI
Sino Biopharmaceutical Presents Lung Cancer Drug Trial Data at US Oncology Society Meeting	May. 23	MT
Sino Biopharmaceutical Limited Announces Data from Phase III Study of Benmelstobart in Combination with Anlotinib for First-Line Treatment of Sq-NSCLC	May. 23	CI
Sino Biopharmaceutical Gets FDA Nod to Market Cancer Drug	Apr. 25	MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Penpulimab Injection by the US FDA	Apr. 25	CI
Sino Biopharmaceutical Gets China Nod for Hematologic Tumor Drug Trial	Apr. 10	MT
Sino Biopharmaceutical Says Tqb3019 (Btk Protac) Approved For Clinical Trial By NMPA	Apr. 09	RE
Biopharmaceutical Limited Announces Application for Clinical Trial of "TQB3019 (BTK PROTAC)" Approved by NMPA	Apr. 09	CI
Sino Biopharmaceutical's Anti-Tumor Drug Gets Implied Approval from China	Apr. 04	MT
Sino Biopharmaceutical Limited Announces Approval for Clinical Trial of TQB2101 (RR1 ADC)	Apr. 03	CI
Sino Biopharmaceutical Says Positive Results On Phase 3 Study Of Culmerciclib In Combination With Fulvestrant	Mar. 24	RE
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Culmerciclib in Combination with Fulvestrant for First-Line Treatment of H-Positive and HER2-Negative Breast Cancer	Mar. 24	CI
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$5.52 From HK$6.42, Keeps at Buy	Mar. 21	MT
Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 20	CI
Sino Biopharmaceutical's Drug Study Shows 85.2% Failure-Free Survival Rate for 12 Months	Mar. 11	MT
Sino Biopharmaceutical Limited Announces Publication of Results from Phase Ib/IIa Clinical Study of "Rovadicitinib"	Mar. 10	CI
Sino Biopharmaceutical Limited(SEHK:1177) dropped from Hang Seng China Enterprises Index	Mar. 06	CI

Chart Sino Biopharmaceutical Limited

Duration

Period

1177: Dynamic Chart

Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicine and Chemical Medicine segment is engaged in the manufacture, sale and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is principally engaged in the long term and short term investments. The Other segment is principally engaged in the related medical and hospital business.

Employees

24,379

Sector

Pharmaceuticals

Calendar

Jun. 15 - Final dividend

More about the company